G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Some GLP-1 users also report fewer cravings for unhealthy ... The drugs in development now are dual agonists (like Mounjaro) and triple agonists, which activate multiple receptors simultaneously ...

One of Sosa’s clients, the 52-year-old fashion consultant, went on Mounjaro last March and has since lost 40 pounds — but she saw muscle on her triceps and legs dwindle. The GLP-1 workout has ...

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Semaglutide (GLP-1) weight-loss drug Wegovy ... Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes.

GLP-1 medications like Ozempic are reshaping the way people snack, with fewer ultra-processed foods and a shift toward nutrient-packed bites. See what’s in and what’s out.

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.

Dr. Mensen adds that tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP agonist, may also be recommended. "Based on the fact that each individual experience with this medication is different ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support Patch Collection—a targeted solution designed to complement individuals ...